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model of cognitive enhancement would be of
benefit as a screening tool in the search for new thera-
pies for cognitive disorders such as Alzheimer’s disease.
This article provides arguments in favor of neurophysi-
ological assessments during performance in psychomet-
ric tests to fulfil such aims.The first part concerns the
basic characterization of event-related potentials (ERPs)
and, in particular, the generators of the cognitive
response called P300, in terms of temporal and spatial
properties.Next,we investigate the effects of both non-
cholinergic and cholinergic drugs and their interaction
in healthy young male and elderly subjects using the
extracted ERP parameter as readout.
Temporal and spatial characterization 
of cognitive responses
ERPs are transient modifications in electromagnetic
brain signals,which are time-locked to cognitive,motor,
or sensory processing.They represent activity directly at
the level of neuronal networks and hence form a good
method for studying the working brain and obtaining
neurophysiological indices of attentional mechanisms
and cognitive function.In so-called “oddball”paradigms,
in which a subject is instructed to count the number of
target stimuli,a positive scalp potential with a maximum
amplitude of around 300 ms is recorded and is referred
to as P300 (Figure 1).Before the emergence of this type
of activation, the brain signals display a sequence of
components related to consecutive steps of information
processing in the central nervous system (CNS), like
encoding of stimulus,orienting reaction,etc.These occur
in certain time-windows during normal functioning,and
the term chronometry is often used. Hence, such elec-
trical responses from the scalp are relevant because they
are the result of a coordinated synchronization in dis-
tributed neuronal populations. Topographic analysis
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In order to stress the importance of P300 responses in
drug development, we describe the spatiotemporal char-
acteristics of this objective, evoked event-related poten-
tial. These brain activations reflect mnemonic function, in
which limbic structures play a role. It is demonstrated that
a pharmacological challenge concerning, for example, the
cholinergic system in young healthy volunteers induces
modifications in P300 reminiscent of the aging brain. We
use this type of observation to build a model in which it
can be verified whether the deterioration can be coun-
teracted by treatment with “cognition-enhancing” drugs.
If we accept the extrapolation of the pharmacological
effects to symptomatology, scalp potential analysis offers
an appropriate tool for the study of drug interactions in
early proof-of-concept models.
Dialogues Clin Neurosci. 2002;4:388-394.
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reveals patterns in agreement with such a hypothesis
(Figure 2, top).The reversal in polarity in the posterior
part (oriented toward the right) suggests the presence of
parietotemporal sources.Several lines of evidence indi-
cate that the sources must be located in deep structures,
such as the hippocampal formation.Multiple generators
located in limbic frontal and inferotemporal brain
regions are described as neuronal substrates,
2,3 as has
been confirmed by positron emission tomography (PET)
imaging
4 and,more recently,by hemodynamic responses
in functional magnetic resonance imaging (fMRI).
5-9
Speculations are made that the underlying generators
are located in medial temporal lobe regions.
A method that is promising to better characterize these
phenomena is the recording of the magnetic fields.
Regarding auditory P300, contradictory results have
been reported,ranging from no response
10 to an effect in
the left hemisphere,
11 or more global activations during
a lexical test
12 or equivalent oddball tasks in the visual
modality.
13 These studies have been carried out either
with gradiometers or with a limited number of sensors,
covering only a small portion of the cortex.We used a
more sensitive method, namely a whole-head magne-
tometer array (148 channels,Magnes 2500 WH,BTI,San
Diego, Calif) to study the equivalent P300 generators.
Figure 2 displays a top view (bottom left) and lateral
view (bottom right) of the average activation pattern
obtained in the P300 paradigm for the same views as for
the electrical responses (Figure 2, top).As can be seen,
a highly structured pattern with a positive and a nega-
tive pole, called the magnetic dipole, is present.A simi-
lar but mirror-imaged pattern is present over the right
hemisphere.The rotation by about 90° with respect to
the orientation of the electrical pattern should be noted.
Many researchers have developed three-dimensional
reconstruction or source localization techniques.With
my colleague L. Soufflet, we have also implemented
such noninvasive imaging procedures. We recently
demonstrated that analysis using magnetoencephalog-
raphy (MEG) can model this type of cognitive response,
yielding, as expected, a relatively simple solution of the
complex neuronal interactions,by a preliminary process
of localizing the sources using a spherical model of the
head,topologically adapted for the anatomical substrate,
as shown in Figure 3.The locations of current vectors,
which explain more than 90% of the observed brain sig-
nals, have their origin in the hippocampal formation.
Hence,limbic structures contribute to information pro-
cessing during cognitive discrimination in the auditory
paradigm.
Functional aspects and neuropharmacology
P300 characteristics such as amplitude and latency are
altered during aging.
14,15The pathophysiological state is
reflected in the brain activity.
16-18 Moreover,the deterio-
ration effect has been shown to coincide with the clini-
cal severity of mental illness in demented patients.
19-21
The activation pattern has been shown to be under
cholinergic control: scopolamine is able to attenuate or
even abolish the P300 response in young healthy volun-
teers.
22-24 Figure 4 shows the postdosing evolution and
statistical comparison of the effect of the cholinergic
antagonist scopolamine (0.5 mg, subcutaneous [SC],
top).As can be seen, a significant frontocentral attenu-
ation is present in healthy volunteers (upper right
Figure 1. Example of an averaged P300 response. The methods for
event-related potential (ERP) recordings are described else-
where.
1 In brief, 28 electroencephalography (EEG) leads were
recorded using an ear-linked reference. Subjects listened to a
series of two tones, presented binaurally, with a frequency of
500 Hz for frequent tones and 2000 Hz for infrequent tones,
in a soundproof and electrically shielded room; they were asked
to keep their eyes closed and to count the infrequent tones
silently. Sampling rate was 250 samples per second with filter
settings at 0.5 to 70 Hz (24 dB/oct). The average amplitude
between 230 and 352 ms is calculated to yield areas under the
response curves (P3 surface) for each individual subject and
time point.
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Target tonepanel). Such effects parallel the deterioration in
mnemonic capacities induced by the drug (see below).
Acetylcholinesterase (AchE) inhibitors,on the contrary,
induce increases in these topographic regions after oral
administration.Indeed,oral administration of donepezil,
a representative of the class of nootropic compounds,
induces the opposite effects (Figure 4,bottom).This type
of effect is in full agreement with the existing litera-
ture.
26,27
The message so far is that the relationship between neu-
ropharmacology of the cholinergic system,which is fairly
straightforward, on the one hand, and evoked (cogni-
tive) responses reflecting conscious attention,which fits
with the functional brain anatomy of limbic circuitry,on
the other, form an ideal basis to study drug interaction
in research in the field of psychiatric disorders.
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Figure 2. Topographic distribution of P300 responses. Top: electrical activity from scalp electrodes top view (left) and lateral view (right) of the left sur-
face with the nose pointing toward the left. Bottom: the same as above, but for the magnetic measurement at several millimeters from
the scalp. EEG, electroencephalography.
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Figure 3. Limbic sources of P300m dipoles. Three-dimensional recon-
struction of the major sources explaining the pattern presented
in Figure 2. Note the location in the posterior part of the hip-
pocampal formation.Markers of drug effects on brain function - Boeijinga Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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Proof of concept
The “pseudo–state/trait marker” concept
As mentioned previously,the aging brain provides a nat-
ural decline in the properties of the cognitive response,
such as the P300 waves (Figure 5, top). Comparison of
healthy male subjects aged 55 years and older with
young subjects aged between 18 and 35 years yields sig-
nificant attenuation in large parietal and temporal scalp
regions.On basis of this change in CNS state,a proof of
concept can be proposed by administration of equiva-
lent drugs presumed to be beneficial and by verifying
the presence of improvement in healthy elderly subjects.
The idea is that of a selective marker because in the
elderly particular nootropic drugs are able to signifi-
cantly restore P300.
28
Due to the lack of clinical efficacy of AchE inhibitors,
29
more and more alternative mechanisms of action on cen-
tral receptors or enzymes are being explored.An exam-
ple of the effect of a noncholinergic drug is given in Figure
5 (bottom).
30 Indeed,a clear-cut indication of recovery can
be observed,even though the increase in absolute terms
is modest.
The concept of a pharmacological model in young 
volunteers
The established approach in behavioral neuropsy-
chopharmacology is the use of a pharmacological chal-
lenge to reversibly provoke symptoms.As an example,we
refer to the model that makes use of the comparison of
performance in a battery of psychometric tests (eg,digit
vigilance speed) and recording of continuous electrical
cerebral activity.
31 Both types of examination undergo
changes with scopolamine and some of these effects have
been shown to be reversed by AchE inhibitors.
Hence P300 responses constitute a useful tool in neu-
ropsychopharmacology in exactly the same way as con-
tinuous electrical cerebral activity,for the reasons shown
in Figure 4. Interestingly, manipulation with benzodi-
azepines in order to provoke—like scopolamine—symp-
toms of cognitive impairment at the clinical level in,for
example,free word recall,
32 induces similar collapses in
Figure 4. Cholinergic control of P300 in young healthy volunteers. Top: Mapping result show the dramatic deterioration under scopolamine (0.5
mg, subcutaneous). P values are issued after multiple nonparametric comparisons (Wilcoxon) between two experimental conditions for each
electrode with significance levels coded in the rainbow scale at the lower right-hand side. (Increase in red; decrease in blue, for details the
reader is referred Statistical Decision Tree or SDT
25.) Bottom: Postdosing mapping of donepezil (5 mg) yields enhancement of P300 responses.
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33-36 (eg,lorazepam, Figure 6) and visually
37
evoked cognitive responses.
In our experience,the effects on neurophysiological para-
meters are often much more sensitive than the effects
seen in performance changes.Schematically,the proce-
dure can be summarized as follows:
• Drug 1 induces a simulation of the acute state of “non-
treated”patient (symptom provocation).
• Drug 2 is used to verify its potency to (partially) reverse
the deterioration (validation for pharmacotherapy).
An example of the reversal of the challenge-induced dete-
rioration (drug 1) with an AchE inhibitor (drug 2) is
shown in Figure 6 (for study design see reference 38).The
interesting aspect of such a model is the possibility of pre-
venting the induction of symptoms by compounds with-
out direct cholinergic effects
39 and using a neurophysio-
logical readout as surrogate marker at the same time.
Perspectives and conclusions
Using the P300 as a marker of relevant brain function,a
pharmacological challenge in young healthy volunteers to
provoke symptoms like in aging can be counteracted by
treatment with cognition-enhancing drugs.A longer pre-
treatment with nootropics (such as AchE inhibitors),
which simulates more closely the clinical setting,may have
more persistent effects on challenge-induced deteriora-
tion in P300, but this hypothesis remains to be investi-
gated.A lower dose of symptom-provoking agents asso-
ciated with P300 changes may also increase the
Clinical research
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Figure 5. Age-related modifications in P300. Top left: Average curves for elderly (aged >55 years; blue lines) and young volunteers (gray lines) for sev-
eral scalp positions. Top right: Statistical comparison between elderly and young subjects. Bottom left: Average curves in untreated (placebo)
and treated elderly male volunteers. Bottom right: Statistical comparison showing significant improvement.
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Figure 6. Superimposed average P300 responses for baseline conditions
(light-blue lines) and after a drug challenge (dark-blue lines).
The effect of an acetylcholinesterase (AchE) inhibitor (gray lines)
restores the deteriorated signal in the direction of baseline lev-
els. Inset: statistical mapping of treatment drug 2 + drug 1 ver-
sus drug 1 alone. Scaling as in Figure 4.
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Marcadores objetivos del efecto de fármacos
en la función cerebral a partir del registro de
la actividad eléctrica del cuero cabelludo en
voluntarios sanos
Para enfatizar la importancia de las respuestas de
la onda P300 en el desarrollo de fármacos, nosotros
describimos las características témporo-espaciales
de este potencial evocado objetivo que describe
una respuesta a un estimulo. Estas activaciones
cerebrales reflejan la función mnémica en la cual
juegan un papel las estructuras límbicas. Está
demostrado que un desafío farmacológico, que se
relacione por ejemplo con el sistema colinérgico en
voluntarios sanos jóvenes, induce modificaciones en
la onda P300 que hacen pensar en un cerebro enve-
jecido. Nosotros utilizamos este tipo de observación
para construir un modelo en el cual se pueda veri-
ficar si el deterioro se puede neutralizar mediante
el tratamiento con fármacos “aumentadores de la
cognición.” De aceptar la extrapolación de los efec-
tos farmacológicos a la sintomatología, el análisis
de la actividad eléctrica del cuero cabelludo ofrece
una herramienta apropiada para el estudio de las
interacciones de fármacos en los modelos iniciales
de “proof of concept.”  
Les marqueurs objectifs des effets médica-
menteux sur la fonction cérébrale à partir
d’enregistrements de l’activité électrique sur
le cuir chevelu de volontaires sains
Afin de souligner l’importance des réponses cogni-
tives appelées P300 dans le développement des
molécules, nous décrivons les caractéristiques tem-
porospatiales de ces potentiels évoqués objectifs en
réponse à une stimulation cible. Ces activations
cérébrales reflètent la fonction mnésique dans
laquelle les structures limbiques jouent un rôle. Il a
été démontré qu’un test de provocation pharma-
cologique utilisant, par exemple, le système choli-
nergique chez de jeunes volontaires sains, entraî-
nait des modifications des réponses P300 rappelant
celles retrouvées dans le cerveau vieillissant. Nous
avons utilisé ce type d’observations pour construire
un modèle qui permet de vérifier si cette détério-
ration peut être contrebalancée par des molécules
« procognitives ». Si l’on accepte l’extrapolation des
effets pharmacologiques à la symptomatologie,
l’analyse des potentiels au niveau du cuir chevelu
constitue un outil approprié pour l’étude des inter-
actions médicamenteuses dans des modèles utilisés
en phase précoce de démonstration de concept.
probability of detecting an antagonism in this model.The
first steps toward a validation of a surrogate marker can
now be considered as accomplished. ❏
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